Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
09 2019
Historique:
received: 12 10 2018
revised: 18 01 2019
accepted: 10 05 2019
pubmed: 6 6 2019
medline: 21 10 2020
entrez: 6 6 2019
Statut: ppublish

Résumé

The province of British Columbia (BC) Canada has experienced a rapid increase in illicit drug overdoses and deaths during the last 4 years, with a provincial emergency declared in April 2016. These deaths have been driven primarily by the introduction of synthetic opioids into the illicit opioid supply. This study aimed to measure the combined impact of large-scale opioid overdose interventions implemented in BC between April 2016 and December 2017 on the number of deaths averted. We expanded on the mathematical modelling methodology of our previous study to construct a Bayesian hierarchical latent Markov process model to estimate monthly overdose and overdose-death risk, along with the impact of interventions. Overdose events and overdose-related deaths in BC from January 2012 to December 2017. The interventions considered were take-home naloxone kits, overdose prevention/supervised consumption sites and opioid agonist therapy MEASUREMENTS: Counterfactual simulations were performed with the fitted model to estimate the number of death events averted for each intervention and in combination. Between April 2016 and December 2017, BC observed 2177 overdose deaths (77% fentanyl-detected). During the same period, an estimated 3030 (2900-3240) death events were averted by all interventions combined. In isolation, 1580 (1480-1740) were averted by take-home naloxone, 230 (160-350) by overdose prevention services and 590 (510-720) were averted by opioid agonist therapy. A combined intervention approach has been effective in averting overdose deaths during British Columbia's opioid overdose crisis in the period since declaration of a public health emergency (April 2016-December 2017). However, the absolute numbers of overdose deaths have not changed.

Sections du résumé

BACKGROUND AND AIMS
The province of British Columbia (BC) Canada has experienced a rapid increase in illicit drug overdoses and deaths during the last 4 years, with a provincial emergency declared in April 2016. These deaths have been driven primarily by the introduction of synthetic opioids into the illicit opioid supply. This study aimed to measure the combined impact of large-scale opioid overdose interventions implemented in BC between April 2016 and December 2017 on the number of deaths averted.
DESIGN
We expanded on the mathematical modelling methodology of our previous study to construct a Bayesian hierarchical latent Markov process model to estimate monthly overdose and overdose-death risk, along with the impact of interventions.
SETTING AND CASES
Overdose events and overdose-related deaths in BC from January 2012 to December 2017.
INTERVENTIONS
The interventions considered were take-home naloxone kits, overdose prevention/supervised consumption sites and opioid agonist therapy MEASUREMENTS: Counterfactual simulations were performed with the fitted model to estimate the number of death events averted for each intervention and in combination.
FINDINGS
Between April 2016 and December 2017, BC observed 2177 overdose deaths (77% fentanyl-detected). During the same period, an estimated 3030 (2900-3240) death events were averted by all interventions combined. In isolation, 1580 (1480-1740) were averted by take-home naloxone, 230 (160-350) by overdose prevention services and 590 (510-720) were averted by opioid agonist therapy.
CONCLUSIONS
A combined intervention approach has been effective in averting overdose deaths during British Columbia's opioid overdose crisis in the period since declaration of a public health emergency (April 2016-December 2017). However, the absolute numbers of overdose deaths have not changed.

Identifiants

pubmed: 31166621
doi: 10.1111/add.14664
pmc: PMC6684858
mid: NIHMS1030966
doi:

Substances chimiques

Narcotic Antagonists 0
Naloxone 36B82AMQ7N

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1602-1613

Subventions

Organisme : NIDA NIH HHS
ID : U01 DA021525
Pays : United States
Organisme : Natural Science and Engineering Research Council Discovery Grant
ID : RGPIN-2015-04611
Pays : International
Organisme : Natural Sciences and Engineering Research Council of Canada
Pays : International
Organisme : CIHR
Pays : Canada

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Society for the Study of Addiction.

Références

Drug Alcohol Depend. 2014 Dec 1;145:48-68
pubmed: 25456324
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15693-7
pubmed: 17030819
J R Stat Soc Ser C Appl Stat. 2010 Mar;59(2):233-253
pubmed: 20383261
Lancet. 2011 Apr 23;377(9775):1429-37
pubmed: 21497898
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207
pubmed: 18425880
Drug Alcohol Depend. 2006 Jul 27;83(3):193-8
pubmed: 16356659
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
BMJ. 1999 Aug 21;319(7208):508-12
pubmed: 10454409
Addiction. 2010 Jun;105(6):1049-54
pubmed: 20219056
PeerJ Comput Sci. 2023 Sep 1;9:e1516
pubmed: 37705656
Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):248-251
pubmed: 29911821
Int J Drug Policy. 2018 May;55:61-69
pubmed: 29524734
BMJ. 2015 Jun 09;350:h2750
pubmed: 26058820
Am J Public Health. 2018 Oct;108(10):1394-1400
pubmed: 30138057
Lancet Public Health. 2018 May;3(5):e205-e206
pubmed: 29678560
Addiction. 2014 Feb;109(2):177-81
pubmed: 23692335
Stat Methods Med Res. 2009 Jun;18(3):253-70
pubmed: 19036911
Drug Alcohol Depend. 2007 Dec 1;91(2-3):228-35
pubmed: 17669601
Addiction. 2016 May;111(5):883-91
pubmed: 26642424
Med Decis Making. 2015 Feb;35(2):148-61
pubmed: 23886677
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
MMWR Morb Mortal Wkly Rep. 2017 Jul 07;66(26):697-704
pubmed: 28683056
Lancet Public Health. 2018 May;3(5):e204
pubmed: 29709648
Addict Behav. 2017 Aug;71:104-106
pubmed: 28325710
Int J Drug Policy. 2018 May;55:31-39
pubmed: 29482150
Ann Intern Med. 2013 Jan 1;158(1):1-9
pubmed: 23277895
Lancet Public Health. 2018 May;3(5):e218-e225
pubmed: 29678561
MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):382-386
pubmed: 28406883
Int J Drug Policy. 2019 Sep;71:157-163
pubmed: 30691944
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272

Auteurs

Michael A Irvine (MA)

Institute of Applied Mathematics, University of British Columbia, Vancouver, BC, Canada.
British Columbia Centre for Disease Control, Vancouver, BC, Canada.

Margot Kuo (M)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.
School of Population and Public Health, University of British Columbia, BC, Canada.

Jane A Buxton (JA)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.
School of Population and Public Health, University of British Columbia, BC, Canada.

Robert Balshaw (R)

George and Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, MB, Canada.

Michael Otterstatter (M)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.

Laura Macdougall (L)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.

M-J Milloy (MJ)

British Columbia Centre on Substance Use, Vancouver, BC, Canada.

Aamir Bharmal (A)

Fraser Health, Surrey, British Columbia, Canada.

Bonnie Henry (B)

Ministry of Health, Victoria, British Columbia, Canada.

Mark Tyndall (M)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.
School of Population and Public Health, University of British Columbia, BC, Canada.

Daniel Coombs (D)

Institute of Applied Mathematics, University of British Columbia, Vancouver, BC, Canada.

Mark Gilbert (M)

British Columbia Centre for Disease Control, Vancouver, BC, Canada.
School of Population and Public Health, University of British Columbia, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH